Gattis WA - Search Results

1

Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.

Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J. Fonarow GC, et al. Among authors: gattis wa. Am Heart J. 2004 Jul;148(1):43-51. doi: 10.1016/j.ahj.2004.03.004. Am Heart J. 2004. PMID: 15215791

2

Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4).

O'Connor CM, Gattis WA, Adams KF Jr, Shah MR, Kobrin I, Frey A, Gheorghiade M. O'Connor CM, et al. Among authors: gattis wa. Am Heart J. 2002 Oct;144(4):583-8. doi: 10.1016/s0002-8703(02)00127-8. Am Heart J. 2002. PMID: 12360152 Clinical Trial.

3

Treatment gaps in the pharmacologic management of heart failure.

Gheorghiade M, Gattis WA, O'Connor CM. Gheorghiade M, et al. Among authors: gattis wa. Rev Cardiovasc Med. 2002;3 Suppl 3:S11-9. Rev Cardiovasc Med. 2002. PMID: 12447157 Review.

4

The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications.

Gattis WA, O'Connor CM, Gheorghiade M. Gattis WA, et al. Rev Cardiovasc Med. 2002;3 Suppl 3:S48-54. Rev Cardiovasc Med. 2002. PMID: 12447162 Clinical Trial.

5

Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure.

O'Connor CM, Gattis WA, Teerlink JR, Adams KF Jr, Gheorghiade M. O'Connor CM, et al. Among authors: gattis wa. Am Heart J. 2003 Feb;145(2 Suppl):S47-50. doi: 10.1067/mhj.2003.153. Am Heart J. 2003. PMID: 12594451 No abstract available.

6

Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.

Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M; IMPACT-HF Investigators and Coordinators. Gattis WA, et al. J Am Coll Cardiol. 2004 May 5;43(9):1534-41. doi: 10.1016/j.jacc.2003.12.040. J Am Coll Cardiol. 2004. PMID: 15120808 Free article. Clinical Trial.

7

Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction.

Bart BA, Gattis WA, Diem SJ, O'Connor CM. Bart BA, et al. Among authors: gattis wa. Am J Cardiol. 1997 Apr 15;79(8):1118-20. doi: 10.1016/s0002-9149(97)00060-x. Am J Cardiol. 1997. PMID: 9114778

8

Current and novel pharmacologic approaches in advanced heart failure.

O'Connor CM, Gattis WA, Swedberg K. O'Connor CM, et al. Among authors: gattis wa. Am Heart J. 1998 Jun;135(6 Pt 2 Su):S249-63. doi: 10.1016/s0002-8703(98)70254-6. Am Heart J. 1998. PMID: 9630089 Review. No abstract available.

9

Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?

Gattis WA, Larsen RL, Hasselblad V, Bart BA, O'Connor CM. Gattis WA, et al. Am Heart J. 1998 Jul;136(1):43-8. doi: 10.1016/s0002-8703(98)70180-2. Am Heart J. 1998. PMID: 9665217

10

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. O'Connor CM, et al. Among authors: gattis wa. Am Heart J. 1999 Jul;138(1 Pt 1):78-86. doi: 10.1016/s0002-8703(99)70250-4. Am Heart J. 1999. PMID: 10385768 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters